New York State Teachers Retirement System Decreases Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

New York State Teachers Retirement System lowered its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 3.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 129,119 shares of the biopharmaceutical company’s stock after selling 4,998 shares during the quarter. New York State Teachers Retirement System owned about 0.10% of Dynavax Technologies worth $1,649,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. US Bancorp DE lifted its position in Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies in the 3rd quarter valued at about $45,000. GAMMA Investing LLC boosted its position in shares of Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares during the period. Nisa Investment Advisors LLC raised its position in Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Dynavax Technologies during the 4th quarter worth $71,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

Shares of NASDAQ DVAX opened at $13.33 on Friday. The stock’s 50 day moving average price is $12.82 and its two-hundred day moving average price is $12.03. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.05. The stock has a market capitalization of $1.75 billion, a P/E ratio of 74.06 and a beta of 1.32. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. The business had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DVAX has been the topic of several research analyst reports. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price objective for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Dynavax Technologies in a report on Friday. Finally, StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.